Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 302 across all filing types
Latest filing 2026-06-02 Declaration of Voting R…
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Exercise of options and total voting rights
Declaration of Voting Results & Voting Rights Announcements
2026-06-02 English
Holding(s) in Company
Major Shareholding Notification Classification · 91% confidence The document is an RNS announcement detailing that following a purchase of shares on 5 May 2026, Simon Peace holds 4,121,744 ordinary shares representing approximately 3.30% of the company’s issued share capital. This is a notification of a change in significant share ownership crossing a regulatory threshold (3%). It does not involve director insider trading specifically, but rather a major shareholding notification. Therefore, the appropriate category is Major Shareholding Notification (MRQ).
2026-05-11 English
Grant of patent in Japan
Regulatory Filings Classification · 85% confidence The document is an RNS announcement dated 11 May 2026 from Fusion Antibodies plc regarding the formal grant of a patent in Japan. It is not a financial report, earnings release, or other defined filing type, but a general regulatory/corporate announcement distributed via RNS. Therefore it falls under the fallback category Regulatory Filings (RNS).
2026-05-11 English
Year-end trading statement
Regulatory Filings Classification · 95% confidence The document is a trading update for the financial year ended 31 March 2026, providing unaudited financial highlights, operational progress, R&D updates, cash position, and outlook commentary. It is not a full annual report (10-K) as it lacks comprehensive audited financial statements and detailed disclosures. It is not an earnings release (ER) because it covers a full fiscal year and provides more narrative than just key highlights. It is not a regulatory filing of a certification or attestation type. The document is a trading statement or business update that provides financial and operational information but does not constitute a full annual or interim report. Such documents are typically classified as Regulatory Filings (RNS) in the absence of a more specific category. The document is over 12,000 characters, so it is not a brief announcement of a report publication (RPA). Therefore, the best fit is Regulatory Filings (RNS).
2026-05-05 English
Antibody IP transfer agreement
Regulatory Filings Classification · 85% confidence The document is an RNS announcement from Fusion Antibodies plc regarding an IP transfer agreement. It is not a financial report (annual, interim, earnings release), nor a dividend, share issuance, board change, M&A, or other specified category. It is a generic regulatory announcement of a commercial agreement. Therefore it falls into the fallback category 'Regulatory Filings' (RNS).
2026-03-30 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a formal notification of a share transfer by a Non-Executive Chairman (Simon Douglas) of Fusion Antibodies plc. It explicitly includes the 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR) table, which is the standard regulatory format for reporting director/insider dealings under the UK Market Abuse Regulation. This fits the definition of a Director's Dealing (DIRS) filing.
2026-02-17 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.